You are here

BIOTEK, INC.

Company Information
Address
21-C OLYMPIA AVENUE
WOBURN, MA 01801
United States



Information

UEI: N/A

# of Employees: N/A


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Vaginal Bioprotection by Controlled Acidification

    Amount: $861,833.00

    DESCRIPTION (provided by applicant): A single unobtrusive product capable of protecting women against both disease and pregnancy should gain widespread acceptance. BIOTEK is investigating a new vagina ...

    SBIRPhase II2004Department of Health and Human Services National Institutes of Health
  2. Transdermal Buprenorphine for Opiate Antagonist Therapy

    Amount: $765,206.00

    DESCRIPTION (provided by applicant): Opiate antagonist therapy is an important treatment for recently withdrawn opiate addicts. Buprenorphine is a mixed agonist-antagonist which eliminates physiologic ...

    SBIRPhase II2004Department of Health and Human Services National Institutes of Health
  3. Microlayered Erythropoietin Implants

    Amount: $99,975.00

    DESCRIPTION (provided by applicant): BIOTEK has discovered a unique processing method for the efficient and safe formulation of peptides or proteins in polylactide-co-glycolide (PLGA) polymer for long ...

    SBIRPhase I2003Department of Health and Human Services National Institutes of Health
  4. TRANSDERMAL BUPRENORPHINE FOR OPIATE ANTAGONIST THERAPY

    Amount: $99,876.00

    DESCRIPTION (provided by applicant): Opiate antagonist therapy is an important treatment for recently withdrawn narcotic addicts. Buprenorphine is a drug with mixed agonist-antagonist properties, whic ...

    SBIRPhase I2002Department of Health and Human Services National Institutes of Health
  5. BUPRENORPHINE MICROCAPSULES FOR HEROIN ADDICTION

    Amount: $99,965.00

    DESCRIPTION (provided by applicant): The overall objective of the program is to develop a new more economical sustained action injectable formulation of -buprenorphine, based on micro ...

    SBIRPhase I2002Department of Health and Human Services National Institutes of Health
  6. INNOVATIVE SINGLE-DOSE HEPATITIS B VACCINE FORMULATION

    Amount: $96,565.00

    DESCRIPTION (provided by applicant): Hepatitis B (HBV) is a serious viral disease that can result in acute massive hepatic necrosis, chronic active hepatitis, and cirrhosis of the liver. HBV vaccines ...

    SBIRPhase I2002Department of Health and Human Services National Institutes of Health
  7. A ONE YEAR ESTROGEN/PROGESTIN IMPLANT

    Amount: $0.00

    This program targets a one-year biodegradable estrogen/progestin implant for postmenopausal hormone replacement therapy. Estradiol plus levonorgestrel will be incorporated into an innovative implant d ...

    SBIRPhase I2002Department of Health and Human Services National Institutes of Health
  8. A ONE YEAR ESTROGEN/PROGESTIN IMPLANT

    Amount: $744,898.00

    This program targets a one-year biodegradable estrogen/progestin implant for postmenopausal hormone replacement therapy. Estradiol plus levonorgestrel will be incorporated into an innovative implant d ...

    SBIRPhase II2002Department of Health and Human Services National Institutes of Health
  9. A NEW METHOD FOR TREATING SLEEP DISORDERS

    Amount: $494,477.00

    DESCRIPTION (provided by applicant): BIOTEK has developed a transdermal melatonin formulation capable of producing flux levels high enough to allow a small patch to deliver a night-time melatonin puls ...

    SBIRPhase II2002Department of Health and Human Services National Institutes of Health
  10. A NEW METHOD FOR TREATING SLEEP DISORDERS

    Amount: $0.00

    DESCRIPTION (provided by applicant): BIOTEK has developed a transdermal melatonin formulation capable of producing flux levels high enough to allow a small patch to deliver a night-time melatonin puls ...

    SBIRPhase I2002Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government